Digital Twins for Managing Health Care Systems: Rapid Literature Review.
Safa Elkefi, Onur Asan
https://pubmed.ncbi.nlm.nih.gov/35972776/Actively Recruiting
Led by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Updated on 2026-08-28
20
Participants Needed
1
Research Sites
N/A
Total Duration
This research aims to evaluate the use of the STRATIF-AI platform and digital twin technology during the secondary prevention phase in adults with stroke, Moyamoya disease, and Cerebral Amyloid Angiopathy CAA. The study compares patients using the STRATIF-AI app alongside standard secondary prevention to those receiving standard secondary prevention alone. Researchers want to understand patients experiences and the usability of the STRATIF-AI platform. Participants are randomly assigned to one of two groups. One group uses the STRATIF-AI app daily to manage their health and may connect wearable devices to the app, while also following standard secondary prevention care. The other group receives only the usual secondary prevention treatments and monitoring. Cognitive and psychological assessments are conducted at the start and after six months for all participants. The group using the app will also participate in interviews to share their feedback about the app. During the study, participants undergo evaluations including cognitive tests like the Montreal Cognitive Assessment MOCA, health and disability surveys, and psychological scales. Researchers collect clinical and socio-demographic data, as well as details about their medical history and current therapies. The study gathers both quantitative data from these assessments and qualitative feedback from interviews to analyze the user experience with the digital twin technology. The total study period includes baseline and six-month follow-up assessments.
CONDITIONS
Application of Digital Twins' Technology in Patients Who Had a Stroke, With Moyamoya Disease and With Cerebral Amyloid Angiopathy (CAA) During the Secondary Prevention Phase: A Proof of Concept Using a Randomized Control Trial (Clinical Study 6, STRATIF-AI Project)
M
Matilde Leonardi, MD
B
Barbara Maistrello
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 6 months
Participants receive either the STRATIF-AI app alongside standard secondary prevention or standard secondary prevention alone. They complete cognitive and psychological assessments at the start and after six months. Those using the app may connect wearable devices and share feedback in interviews.
1 initial visit and 1 follow-up visit
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Safa Elkefi, Onur Asan
https://pubmed.ncbi.nlm.nih.gov/35972776/Mille Nabsen Marwaa, Susanne Guidetti, Charlotte Ytterberg...
https://pubmed.ncbi.nlm.nih.gov/37620982/Tilda Herrgårdh, Vince I Madai, John D Kelleher...
https://pubmed.ncbi.nlm.nih.gov/34000646/Morgan L Prust, Rachel Forman, Bruce Ovbiagele
https://pubmed.ncbi.nlm.nih.gov/38228908/Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Lead Sponsor